Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The LGBTQIA+ community and supporters participated in this year’s Honolulu AIDS Walk on Saturday to raise awareness about the ...

HIV is surging among adults over 50 in sub-Saharan Africa, yet prevention and treatment campaigns still focus mainly on the ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

At its core, the play seeks to raise awareness about HIV prevention, particularly among Black and brown communities that continue to bear a disproportionate burden of this epidemic. As Much As I ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...